Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Scientific Reports|January 4, 2024
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLCCaterina De Rosa, Viviana De Rosa, Concetta Tuccillo, et al.
Nuclear Medicine Communications|February 24, 2023
Nonvisualized sentinel node on preoperative lymphoscintigraphy in primary cutaneous melanoma: an 11-year retrospective surveyTiziano Pallara, Alessio Annovazzi, Renzo Cristiani, et al.
Immunology Letters|September 20, 2024
NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advancesMarco Greppi, Fabiana De Franco, Valentina Obino, et al.
ESMO Open|August 2, 2017
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancerFloriana Morgillo, Morena Fasano, Carminia Maria Della Corte, et al.
Oncotarget|December 18, 2015
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cellsCarminia Maria Della Corte, Vincenza Ciaramella, Concetta Di Mauro, et al.
Cell Death & Disease|May 16, 2018
A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivoLuigi Mele, Francesca Paino, Federica Papaccio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2015
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung CancerCarminia Maria Della Corte, Claudio Bellevicine, Giovanni Vicidomini, et al.
Cancer Treatment Reviews|September 29, 2024
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancerFederico Rebaudi, Fabiana De Franco, Rayan Goda, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 12, 2022
MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancerCarmela Ferri, Anna Di Biase, Marco Bocchetti, et al.
Oncotarget|August 20, 2016
Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compoundsDiego Carrella, Isabella Manni, Barbara Tumaini, et al.
Pageof 7